NCT00373672View on ClinicalTrials.gov

Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

armodafinil (Nuvigil)

armodafinil (Nuvigil)150 mg qd

DRUG

placebo

identical in appearance to active comparator

Trial Locations (1)

37212

Vanderbilt University Medical Center, Nashville

Sponsors

Collaborators (1)

Cephalon
All Listed Sponsors
collaborator

National Alliance for Research on Schizophrenia and Depression

OTHER

collaborator

Cephalon

INDUSTRY

lead

Northwestern University

OTHER

NCT00373672 - Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder | Biotech Hunter | Biotech Hunter